SPI 017
Alternative Names: SPI-017; SPL-017Latest Information Update: 21 Feb 2018
Price :
$50 *
At a glance
- Originator Sucampo Pharmaceuticals
- Class Antidementias; Fatty acids; Neuroprotectants; Vascular disorder therapies
- Mechanism of Action Chloride channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Pain; Peripheral arterial disorders
Most Recent Events
- 13 Feb 2018 Sucampo Pharmaceuticals has been acquired by Mallinckrodt
- 18 Mar 2013 Discontinued - Phase-I for Peripheral arterial disorders in Japan (IV)
- 18 Mar 2013 Phase-II clinical trials in Pain associated with lumbar spinal stenosis in USA (IV)